Gastric Cancer News

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer (February 6, 2017)

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer... Continue Reading

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer? (December 8, 2016)

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP),... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (June 28, 2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (June 6, 2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced... Continue Reading

February: Gallbladder and Bile Duct Awareness Month (February 18, 2016)

Located underneath the liver, the gallbladder is responsible for the concentration and storage of bile which helps to digest the fats in food as they pass through the intestines. Bile is either released from the liver directly into ducts that carry it... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

Gastric Cancer Risk Factors You Need to Know (February 8, 2016)

Successful treatment for stomach or gastric cancer starts with early detection. Most cases of stomach cancer are diagnosed in the advanced stages as there is no routine test for early detection. This makes it very important for people to know their risk... Continue Reading

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy (January 4, 2016)

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing... Continue Reading

Lynparza Improves Overall Survival in High-Risk Gastric Cancer (September 9, 2015)

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers... Continue Reading

Latest Gastric Cancer News By Stage


Recurrent Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (June 6, 2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (August 10, 2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (February 12, 2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity... Continue Reading

More Recurrent Gastric Cancer

Screening/Prevention Gastric Cancer

Gastric Cancer Risk Factors You Need to Know (February 8, 2016)

Successful treatment for stomach or gastric cancer starts with early detection. Most cases of stomach cancer are diagnosed in the advanced stages as there is no routine test for early detection. This makes it very important for people to know their risk... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

Scientific Review Suggests Aspirin Significantly Cuts Cancer Rates (August 18, 2014)

A recent review of several studies confirms that taking a small daily dose of aspirin significantly reduces the risk of developing – or dying from several kinds of cancer.(1) Several clinical studies have suggested that aspirin can reduce the risk... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

More Screening/Prevention Gastric Cancer

Stages I-II Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy (January 4, 2016)

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing... Continue Reading

Reolysin® Receives FDA Designation for Gastric Cancer (May 14, 2015)

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc. recently announced the designation in a press release. The... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

Adjuvant Radiochemotherapy Demonstrates Benefit in Gastric Cancer (September 25, 2012)

Adjuvant radiochemotherapy provides strong and persistent benefit in patients who have undergone curative gastric resection, according to the long-term results of a study published in the Journal of Clinical Oncology.[1] Gastric cancer refers to cancer... Continue Reading

More Stages I-II Gastric Cancer

Stages III-IV Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (June 28, 2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (June 6, 2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced... Continue Reading

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy (January 4, 2016)

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing... Continue Reading

Lynparza Improves Overall Survival in High-Risk Gastric Cancer (September 9, 2015)

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers... Continue Reading

More Stages III-IV Gastric Cancer